Navigation Links
Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
Date:2/22/2010

SAN DIEGO and OSAKA, Japan, Feb. 22, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that the companies have selected the combination treatment of pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin, for advancement toward Phase 3 development. The decision to advance the program followed encouraging results from a 52-week blinded, placebo-controlled Phase 2 extension study. The pramlintide/metreleptin combination met the key target criteria of sustained and robust weight loss.

"There is an enormous unmet need to help reduce the individual and economic burden of obesity," said Christian Weyer, M.D., vice president, medical development at Amylin Pharmaceuticals. "Through our global co-development and commercialization agreement with Takeda, we are committed to developing innovative therapies to help the millions of people who need better solutions to manage obesity. Today's announcement is an important step forward in helping us make good on that commitment."

"We are pleased with the results of the Phase 2 extension study for the pramlintide/metreleptin combination therapy," said Nancy Joseph-Ridge, M.D., general manager of Takeda's Pharmaceutical Development Division. "This potential new therapy continues to build on our commitment to the management of obesity."

In this extension of a 28-week Phase 2 dose-ranging study, patients who continued treatment with pramlintide/metreleptin for a total of 52 weeks demonstrated sustained weight loss, whereas those continuing on placebo regained almost all of their weight. Consistent with results at 28 weeks, the most robust efficacy was seen in patients with a body mass index (BMI) less than 35 kg/m2.

The combination therapy appeared to be generally well tolerated through 52 weeks, with nausea and injection site adverse events observed as the most common side effects on initiation of pramlintide or metreleptin in combination treatment. Following initiation of therapy, these adverse events occurred at a reduced rate over time in patients continuing combination therapy.

Results from the 28-week portion of this Phase 2 study have been previously reported. Patients who completed the 28-week study had the option to enroll in an extension protocol that assessed longer-term safety and efficacy of various dose combinations of pramlintide and metreleptin to a total of 52 weeks. Approximately 275 patients (75% of those eligible) chose to continue in the extension.

Data from this study may be presented in a future medical forum.

Davalintide Status Update

Amylin has also completed a Phase 2 study of davalintide, a second-generation analog of amylin, for the treatment of obesity. In this study, the weight loss efficacy and tolerability profile of davalintide was not improved over pramlintide, and was inferior to that of the pramlintide/metreleptin combination. Based on this information, Amylin and Takeda, as part of their co-development and commercialization agreement, have decided to halt further development of davalintide at this time.

About Obesity

Obesity is a chronic disease that affects over 400 million people worldwide and is linked to increased health risk of several medical conditions. According to The Obesity Society, obesity is the second leading cause of preventable death in the United States. The total direct and indirect cost attributed to overweight and obesity health issues exceeds $140 billion in the United States each year. Obesity is also rapidly becoming a major health problem in industrialized nations and many developing countries.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

About Takeda

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

Forward-Looking Statements

This press release contains forward-looking statements about Takeda and Amylin, which involve risks and uncertainties. The actual results for each company could differ materially from those discussed due to a number of risks and uncertainties, including that the companies' obesity co-development and commercialization collaboration will not achieve the results we expect; our clinical trials may not start when planned, be completed in a timely manner and/or confirm previous results; our clinical studies may not be predictive; our product candidates, including pramlintide/metreleptin, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process.

With respect to Amylin, these and additional risks and uncertainties are described more fully in Amylin's most recently filed SEC documents, including its Form 10-Q. Amylin undertakes no duty to update these forward-looking statements.

SOURCE Amylin Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.amylin.com
http://www.takeda.com

'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amylin Pharmaceuticals to Webcast Year-End Financial Results
2. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
3. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
4. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
9. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
10. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
11. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Feb. 21, 2017  IBM (NYSE: IBM ) Research has ... detect abnormalities of the eye,s retina. The Melbourne ... of Watson to recognize abnormalities in retina images, which could ... their early identification of patients who may be at risk ... of blindness in the developed world. The ...
(Date:2/21/2017)... , Feb. 21, 2017 Cognitive ... This technique is allowing a previously unattainable level ... Due to this ability, it is anticipated that ... US$ 4 Billion by 2022. The growth of ... advancements in computing platforms, rising installation of cognitive ...
(Date:2/21/2017)... 21, 2017 Scientists From Two ... by Plastic Industry  ... STEER, creator of advanced materials ... the fields of plastics, pharmaceuticals, food and nutraceuticals, biomaterials and ... Darmstadt, Germany , a leading science ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Hanna Boys ... at PolicyLink, will be the keynote speaker at its second Professional Networking Breakfast ... Color Framework, which develops comprehensive strategies to create and expand opportunities for boys ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals ... problems directly related to surgery, treatment, therapy and management. Regular exercise in proper ... qualities of life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based ... predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, ... by giants including Accenture, GE Ventures, and Software AG , will bring ...
(Date:2/21/2017)... ... February 21, 2017 , ... A February 6 article on Healio ... It found that the treatments have led to significant improvements in weight loss and ... efforts. It also noted very few problematic results relating to the treatment. Beverly Hills ...
Breaking Medicine News(10 mins):